Contact this trialFirst, we need to learn more about you.
Histone Deacetylase Inhibitor
Triple Therapy for Bladder Cancer
Recruiting1 awardPhase 1
Salt Lake City, Utah
This trial tests a combination of two drugs, durvalumab and belinostat, for treating advanced urothelial cancer. It targets patients whose cancer has spread or cannot be surgically removed. Durvalumab helps the immune system attack cancer, and belinostat stops proteins that help cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service